Positron Emission Tomography
PET RADIOPHARMACEUTICALS facility in PRAGUE
The first department of PET Radiopharmaceuticals has its premises on the first floor of the PET CENTRUM PRAHA, a facility built inside the compound of the Na Homolce Hospital as an international project carried out in cooperation with the International Atomic Energy Agency. The second floor houses the clinical section of the Nuclear Department of the Na Homolce Hospital.
Production:
The facility is equipped to develop and manufacture radiopharmaceutical agents tagged using positron emitters (18F, 15O, 11C, 13N). The resulting positron radiopharmaceuticals find their application inpositron emission tomography. Currently, the facility produces solely 18FDG (i.e. glucose tagged with fluorine 18F). The PET Radiopharmaceuticals Dept. outputs this positron radiapharmaceutical preparation under the name of Fludeoxyglukosa inj.
Fludeoxyglukosa inj. | |
| Registration No.: | 88 / 320 / 01 - C |
| Active substance: | Fludeoxyglucosum (18F) 100 - 1500 MBq |
| Use: | Fludeoxyglucose is a radio-diagnostics agent employed to monitor the local rate of glucose utilization applying the methods of PET or PET/CT as the indicators of tissue viability. Conveyed by active transportation devices, the substance penetrates to cells in a rate commensurate with the rate of glucose utilization - it undergoes the process of phosphorylation but no further process of metabolizing. The concentration of the (18F)-fluordeoxyglucose in a tissue will also depend on the enzymatic apparatus of cells and their level of blood perfusion. |
| Period of use: | 8 hours from the time of standardization |
| Storage: | from 15 °C to 25 °C. |
| Package sizes: | 0,5; 1; 2; 3; 4; 5; 6; 7; 8; 9; 10; 12; 15 GBq in 1 bottle |
| Download: | Summary of the preparation data |
Contact:
Ing. Michal Antoš
Head of PET Radiopharmaceuticals Dept.
Tel: +420 257090616, +420 257090620
E-mail: ami@ujv.cz
PET RADIOPHARMACEUTICALS facility in BRNO
The second department of PET Radiopharmaceuticals has its premises in the basement and on the ground floor of the PET CENTRUM BRNO, a facility built inside the compound of the Masaryk Institute of Oncology co-financed by European funds. The second floor houses the clinical section of the Nuclear Department of the Masaryk Institute of Oncology.
Production:
The facility is equipped to develop and manufacture radiopharmaceutical agents tagged using positron emitters (18F, 15O, 11C). The resulting positron radiopharmaceuticals find their application inpositron emission tomography. At present, the facility produces exclusively 18FDG (i.e. glucose tagged with fluorine 18F). The PET Radiopharmaceuticals Dept. outputs this positron radiapharmaceutical preparation under the name of Fludeoxyglukosa inj.
Fludeoxyglukosa inj. | |
| Registration No.: | 88 / 320 / 01 - C |
| Active substance: | Fludeoxyglucosum (18F) 100 - 1500 MBq |
| Use: | Fludeoxyglucose is a radio-diagnostics agent employed to monitor the local rate of glucose utilization applying the methods of PET or PET/CT as the indicators of tissue viability. Conveyed by active transportation devices, the substance penetrates to cells in a rate commensurate with the rate of glucose utilization - it undergoes the process of phosphorylation but no further process of metabolizing. The concentration of the (18F)-fluordeoxyglucose in a tissue will also depend on the enzymatic apparatus of cells and their level of blood perfusion. |
| Period of use: | 8 hours from the time of standardization |
| Storage: | from 15 °C to 25 °C. |
| Package sizes: | 0,5; 1; 2; 3; 4; 5; 6; 7; 8; 9; 10; 12; 15 GBq in 1 bottle |
| Download: | Summary of the preparation data |
Contact:
Ing. Miloš Orlík
Deputy Head of the PET Radiopharmaceuticals Dept.
Tel: +420 532284604,
E-mail: orl@ujv.cz